[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100547381":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":22,"centralContacts":26,"locations":32,"responsibleParty":55,"collaborators":57,"id":61,"slug":62,"hasResults":63,"nctId":64,"briefTitle":65,"officialTitle":66,"acronym":30,"eligibilityCriteria":67,"healthyVolunteers":63,"sex":68,"minAge":69,"maxAge":30,"enrollmentInfo":70,"targetDuration":30,"studyType":73,"phases":74,"briefSummary":76,"conditions":77,"keywords":30,"overallStatus":35,"whyStopped":30,"lastUpdateSubmitDate":81,"lastUpdatePostDateStruct":82,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":90},{"fullName":5,"class":6},"University of Wisconsin, Madison","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Letermovir for CMV in Transplant Patients","EXPERIMENTAL","Enrolled participants will be converted from treatment with ganciclovir derivatives to letermovir",[13],"Drug: Letermovir",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Letermovir","480 mg taken orally once daily, for 84 days",[9],[21],"Prevymis",[23],{"name":24,"affiliation":5,"role":25},"Sandesh Parajuli, MBBS","PRINCIPAL_INVESTIGATOR",[27],{"name":24,"role":28,"phone":29,"phoneExt":30,"email":31},"CONTACT","(608) 262-2122",null,"sparajuli@medicine.wisc.edu",[33],{"facility":34,"status":35,"city":36,"state":37,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"UW Hospital and Clinics","RECRUITING","Madison","Wisconsin","53792","United States","US",{"type":42,"coordinates":43},"Point",[44,45],-89.40123,43.07305,{"lat":45,"lon":44},[48,51,53],{"name":49,"role":50,"phone":30,"phoneExt":30,"email":30},"Brad Astor, PhD","SUB_INVESTIGATOR",{"name":52,"role":50,"phone":30,"phoneExt":30,"email":30},"Christopher Saddler, MD",{"name":54,"role":50,"phone":30,"phoneExt":30,"email":30},"Jillian Descourouez, PharmD",{"type":56,"investigatorFullName":30,"investigatorTitle":30,"investigatorAffiliation":30,"oldNameTitle":30,"oldOrganization":30},"SPONSOR",[58],{"name":59,"class":60},"Merck Sharp & Dohme LLC","INDUSTRY","100547381","phase-3-letermovir-prevymis-for-cmv-in-kidney-and-pancreas-transplant-recipients-100547381",false,"NCT06407232","Letermovir (Prevymis) for CMV in Kidney and Pancreas Transplant Recipients","An Interventional Study of Letermovir for Secondary Prophylaxis After Treatment of Cytomegalovirus Infection in High Risk (D+\u002FR-) Kidney and Kidney\u002FPancreas Transplant Recipients","Inclusion Criteria:\n\n* undergone kidney or simultaneous kidney\u002Fpancreas transplant\n* high-risk CMV serostatus (D+\u002FR-) at time of transplant\n* develop CMV viremia that necessitates treatment per our institutional protocol (enrolled in the CMV stewardship monitoring initiative)\n* demonstrate proven or presumptive lack of CMI, either by CMI testing or risk factor screening\n* able to provide informed consent to participate\n\nExclusion Criteria:\n\n* contraindication to letermovir or its excipients\n* develop ganciclovir-resistant CMV infection\n* currently participating in any study involving the administration of a CMV vaccine or another CMV investigational agent\n* unable or unwilling, in the opinion of the Investigator, to comply with the protocol\n* pregnant or breastfeeding","ALL","18 Years",{"count":71,"type":72},90,"ESTIMATED","INTERVENTIONAL",[75],"PHASE3","This study is designed to assess how effective letermovir is in preventing recurrence of cytomegalovirus (CMV) infection in adult kidney or kidney\u002Fpancreas transplant recipients who are UW Health patients. Participants will be in the study for about 6 months.",[78,79,80],"Cytomegalovirus Infections","Kidney Transplant Infection","Pancreas Transplant","2026-06-09",{"date":83,"type":84},"2026-06-11","ACTUAL",{"date":86,"type":84},"2024-08-08",{"date":88,"type":72},"2027-08",{"name":5,"class":6},1]